Abstracts tagged "Measurement"

Abstract Number: 2619 • ACR Convergence 2025
What Works? A Consolidated Framework for Implementation Research-Guided Exploration of Patient Safety in Rheumatology Practices
Catherine Nasrallah¹, Cherish Wilson², Christine Hariz³, Alicia Hamblin⁴, Cammie Young⁵, gabriela Schmajuk⁶ and Jinoos Yazdany⁴, ¹University of California San Francisco (UCSF), San Francisco, CA, ²UCSF / SFVA, San Francisco, CA, ³University of California San Francisco (UCSF, San Francisco, CA, ⁴UCSF, San Francisco, CA, ⁵University of California, San Francisco, Oakland, CA, ⁶University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA
Background/Purpose: Despite widespread recognition of persistent patient safety challenges in the U.S. health care system, the development of feasible and scalable solutions has lagged, particularly…
Abstract Number: 2388 • ACR Convergence 2025
Correlation between Activity Index, Organ Damage Index, and HAQ in Systemic Lupus Erythematosus: a single-center study
Carmen Lasa Teja¹, Carmen Bejerano-Herreria², Laura Muñoz-Llopis², Pilar Ortiz-Lavin², Carolina Aguirre-Portilla², Virginia Portilla González³ and Ricardo Blanco⁴, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Riotuerto, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, ⁴Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Systemic Lupus Erythematosus (SLE) presents a highly heterogeneous clinical course and prognosis. In line with EULAR recommendations and treat-to-target (T2T) strategies, comprehensive assessment of…
Abstract Number: 2166 • ACR Convergence 2025
Clinical Disease Activity Index (CDAI) for Rheumatoid Arthritis: A Clinical Educational Workshop
Ahmed Rubia¹, Nancy Olsen², Saurav Suman³, Sharon Banks⁴, Shirley Albano Aluquin¹, Kristie Pepper⁵ and Rayford June⁶, ¹Penn State Milton S. Hershey Medical Cen, Hershey, PA, ²Penn State University/Milton S Hershey, Hershey, PA, ³Penn State Milton S. Hershey Medical Cen, Harrisburg, PA, ⁴Penn State Milton S. Hershey Medical Center, Hershey, PA, ⁵Penn State Milton S. Hershey Medical Cen, Lebanon, PA, ⁶Penn State College of Medicine/Lebanon VA Medical Center, Hummelstown, PA
Background/Purpose: The Clinical Disease Activity Index (CDAI) is one of six assessment measures for rheumatoid arthritis (RA) recommended for management of RA in clinical practice.…
Abstract Number: 2094 • ACR Convergence 2025
Evaluating the Accuracy of Knee Acoustic Emissions Classification of Varus Thrust
Kari Falaas¹, Ahmet Emirdagi², Christopher Nichols² and David Ewart³, ¹University of Minnesota, Minneapolis, ²Georgia Institute of Technology, Atlanta, ³Minneapolis Veterans Affairs Medical Center, Minneapolis
Background/Purpose: Osteoarthritis (OA) of the knee is a leading cause of disability, healthcare expenditures, and is associated with diminished quality of life and increased mortality.…
Abstract Number: 2069 • ACR Convergence 2025
Concordance of low titer positive myositis-specific autoantibodies and myositis-associated autoantibodies on subsequent myositis panel testing.
Nikola Wilk¹, Jocelyn Hui Ching Chow², Ian Smith³, Ronald A. Booth⁴, Nancy Maltez¹, Catherine Ivory¹ and Jodi Warman-Chardon⁵, ¹Department of Medicine, Division of Rheumatology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada., Ottawa, ON, Canada, ²Department of Medicine, Division of General Internal Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Canada., Ottawa, ON, Canada, ³Department of Medicine, Division of Neurology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada., Ottawa, ON, Canada, ⁴Department of Pathology and Laboratory Medicine, The Ottawa Hospital, University of Ottawa & Eastern Ontario Regional Laboratory Association, Ottawa, ON, Canada., Ottawa, ON, Canada, ⁵Department of Medicine, Division of Neurology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada. Department of Medicine and Cellular and Molecular Medicine, Children’s Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON, Canada., Ottawa, ON, Canada
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune connective tissue diseases that commonly affect multiple systems. Myositis-specific autoantibodies (MSA) and myositis-associated autoantibodies…
Abstract Number: 1988 • ACR Convergence 2025
Advancing Vascular Assessment: Combining NIRS-VOT and Ultrasound-Based Brachial Artery Diameter for Improved Diagnostics in Healthy Controls and APS
Soongho Park¹, Julie Mathew¹, Sharon Osgood², Claudia Gomez¹, Eric Leifer¹, Ecem Sevim¹ and Yogendra Kanthi³, ¹NIH, Bethesda, ²NHLBI/NIH, Bethesda, ³National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Near-Infrared Spectroscopy combined with Vascular Occlusion Test (NIRS-VOT) is a non-invasive diagnostic method for assessing microvascular function. However, its diagnostic accuracy is often limited…
Abstract Number: 1977 • ACR Convergence 2025
The Westergren Sedimentation Rate: To Be or Not to Be! The Westergren Sedimentation Rate is being “Killed” but has not “Died”.
John Goldman¹, Michael Goldman² and Glenn R. Parris³, ¹Emory University St Josephs Hospital, Atlanta, GA, ²SENTA Southeastern Ear, Nose, Throat and Allergy, Atlanta, GA, ³PARRIS & ASSOCIATES, Lilburn, GA
Background/Purpose: The Westergren Sedimentation Rate (WSR) is a simple, cost-effective laboratory test commonly used by rheumatologists to assess systemic inflammation. This study was initiated to…
Abstract Number: 1375 • ACR Convergence 2025
86-96% of rheumatoid arthritis (RA) patients with RA who have 0 or 1 swollen joint or tender joint but are classified as moderate/high on RA indices have 1-9 comorbidities recognized on a multidimensional health assessment questionnaire (MDHAQ)
Theodore Pincus¹, Juan Schmukler¹ and Tengfei Li², ¹Rush University Medical Center, Chicago, IL, ²Rush, chicago, IL
Background/Purpose: Rheumatoid arthritis (RA) guidelines suggest management according to “treat-to-target,” with escalation of treatment in patients with moderate/high (M/H) DAS28 (disease activity score 28) or…
Abstract Number: 1253 • ACR Convergence 2025
Patient Reported Outcome Measures: Assessing Resident Physician Acceptance of the Routine Assessment of Patient Index Data 3 Survey and its Impact on Physician-Patient Relationship
Nisha Sapkota¹, Chana Birnbaum², Henna Levitansky², Yevheniia Andriushchenko², Saadia Malik², Melissa Andrade², Sarang Choi² and Sima Terebelo², ¹Interfaith Medical Center, One Broolyn Health, Brooklyn, NY, ²Brookdale Hospital Medical Center, One Brooklyn Health, Brooklyn
Background/Purpose: When treating patients with rheumatological conditions, building a strong physician-patient relationship plays an important role in determining disease outcomes. The Routine Assessment of Patient…
Abstract Number: 0686 • ACR Convergence 2025
Use of a Smartphone App which Incorporates Feedback to Patients to Monitor Systemic Sclerosis-related Digital Ulcers – a Potential New Tool for Remote Clinical Monitoring
Ariane Herrick¹, Paul New², Graham Dinsdale³, Andy Vail², Joanne Manning³, Michael Hughes⁴, Will dixon⁵, Chris Taylor⁵, Mark Dickinson⁵ and Andrea Murray⁶, ¹The University of Manchester, UK, Aberdeen, United Kingdom, ²The University of Manchester, Manchester, United Kingdom, ³Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom, ⁴Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom, ⁵The University of Manchester, Manchester, ⁶University of Manchester, Salford, United Kingdom
Background/Purpose: To facilitate clinical trials we previously developed a smartphone app to allow ‘tracking’ of systemic sclerosis (SSc)-related digital ulcers (DUs) and their associated pain…
Abstract Number: 0852 • ACR Convergence 2025
LEVI-04 Significantly Reduces Bone Marrow Lesions and Symptoms in Knee Osteoarthritis: Results from a Phase II RCT
Simon Westbrook¹, Ali Guermazi² and Philip Conaghan³, ¹Levicept Ltd, Sandwich, United Kingdom, ²Boston University, West Roxbury, MA, ³University of Leeds, Leeds, United Kingdom
Background/Purpose: Bone marrow lesions (BMLs), detectable on MRI as areas of ill-defined high signal intensity on fluid-sensitive sequences, are a common feature of osteoarthritis (OA),…
Abstract Number: 0480 • ACR Convergence 2025
Efficacy and safety of tacrolimus and its serum concentration in patients with rheumatoid arthritis with inadequate response to methotrexate
Chan-Bum Choi, Hanyang University Hosptial for Rheumatic Diseases, Seoul, Republic of Korea
Background/Purpose: Addition of a biologic disease-modifying antirheumatic drug (bDMARD) or targeted synthetic DMARD (tsDMARD) is recommended in patients with rheumatoid arthritis (RA) with inadequate response…
Abstract Number: 0391 • ACR Convergence 2025
Which score fits best? Correlation of clinical indices of Disease Activity and Ultrasound findings in Juvenile Idiopathic Arthritis during Transitional Care
Andrea Pilato¹, Giusyda Tarantino², Maria Isabella Petrone², Angela Aquilani², Emiliano Marasco², Rebecca Nicolai², Fabrizio De Benedetti³, Roberto Giacomelli⁴, Luca Navarini¹ and Silvia Magni-Manzoni², ¹University of Rome Campus Bio-Medico, Rome, Italy, ²Bambino Gesù IRCCS Children's Hospital, Rome, Italy, ³Bambino Gesu Children's Hospital, Rome, Rome, Italy, ⁴i) Clinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Campus Biomedico; ii) Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome "Campus Bio-Medico", Rome, Italy
Background/Purpose: Monitoring disease activity is a crucial aspect of the treat to target paradigm in the management of rheumatic diseases. There are no standardized protocols…
Abstract Number: 0304 • ACR Convergence 2025
Concordance for myositis-specific autoantibody detection between commercial enzyme-linked immunosorbent assay and line blot assay: a multi-center study across the Asia-Pacific region
Takahisa Gono¹, Vidya Limaye², Latika Gupta³, Vikas Agarwal⁴, Ho So⁵, JASMIN RAJA⁶, Warren Weng Seng Fong⁷, Suparaporn Wangkaew⁸, Andrea Low⁹, Akihiro Murakami¹⁰, Kimiko Hasegawa¹⁰, Takuya Isayama¹¹ and Masataka Kuwana¹, ¹Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²Royal Adelaide Hospital, Adelaide, South Australia, Australia, ³School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ⁵Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁶University Malaya, Subang Jaya, Malaysia, ⁷Singapore General Hospital, Singapore, ⁸Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand, ⁹Singapore General Hospital, Singapore, Singapore, ¹⁰Medical & Biological Laboratories co., ltd., Tokyo, ¹¹Medical & Biological Laboratories co., ltd., Tokyo, Japan
Background/Purpose: RNA/protein immunoprecipitation (IP) assays remain the “gold standard” for myositis-specific autoantibody (MSA) detection. However, the requirements for large-scale cell culture and radioisotopes limit its…
Abstract Number: 0294 • ACR Convergence 2025
Clinical relevance of low titer positive myositis-specific autoantibodies and myositis-associated autoantibodies in patients with an underlying malignancy.
Jocelyn Hui Ching Chow¹, Nikola Wilk², Ian Smith³, Ronald A. Booth⁴, Nancy Maltez², Catherine Ivory² and Jodi Warman-Chardon⁵, ¹Department of Medicine, Division of General Internal Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Canada., Ottawa, ON, Canada, ²Department of Medicine, Division of Rheumatology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada., Ottawa, ON, Canada, ³Department of Medicine, Division of Neurology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada., Ottawa, ON, Canada, ⁴Department of Pathology and Laboratory Medicine, The Ottawa Hospital, University of Ottawa & Eastern Ontario Regional Laboratory Association, Ottawa, ON, Canada., Ottawa, ON, Canada, ⁵Department of Medicine, Division of Neurology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada. Department of Medicine and Cellular and Molecular Medicine, Children’s Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON, Canada., Ottawa, ON, Canada
Background/Purpose: The idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune connective tissue diseases that often present with multisystem involvement. Autoantibodies such as myositis-specific…

1
2
3
…
6
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].